Search for Terms or Answers
Psoriatic arthritis patients with inadequate response to tumor necrosis factor (TNF) inhibitors had improvements in their arthritis and psoriasis when treated with the interleukin (IL)-17A blocker ixekizumab (Taltz), according to a phase III study presented here at the
Many topical and OTC products are recommended when treating chronic dry eyes, including omega-3 fatty acids (fish oil or n−3 fatty acids) to relieve symptoms; the NEJM reports that the DREAM trial shows no clinical benefit of n−3 fatty acids for 12 months when compared to placebo.
The identification of a genetic susceptibility locus for systemic juvenile idiopathic arthritis (sJIA) has important implications for treatment of this severe, poorly understood illness, researchers reported.
The Centers for Disease Control and Prevention has a new report showing that from 2004 to 2016, the number of Americans infected by mosquitoes, ticks or fleas tripled from 27,388 in 2004, to 96,075 in 2016.
From 2015 to 2016, these infections rose by 73 percent. This included new Zika and chikungunya virus infections, (41,680 in 2016), followed by Lyme disease (36,429 cases). This may be an underestimation as as many infections are not reported.
Analysis of data from the DANBIO registry of psoriatic arthritis patients treated with tumor necrosis factor inhibitor therapy shows that comorbidities were associated with higher baseline disease activity, shorter TNFi persistence, and reduced clinical response rates to TNFi.
A study from the Veterans Affairs clinics and the National Data Bank of Rheumatic Diseases shows that rheumatoid arthritis (RA) patients who were severely obese had a greater risk of progressive disability compared to overweight patients; that was not explained by their arthritis or inflammation.
Dr. Jack Cush reviews the news and FDA proceedings from the past week on RheumNow.com.
Should celecoxib (Celebrex) be officially declared as no riskier for the heart than other non-steroidal anti-inflammatory drugs (NSAIDs) naproxen and ibuprofen, and do those other NSAIDs interfere with aspirin for cardiovascular prevention?
The French Vasculitis Study Group has published the results of the MAINRITSAN2 trial designed to compare individually tailored versus fixed-schedule rituximab (RTX) reinfusion for remission maintenance in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAVs).
On Monday, April 23rd the FDA convened the Arthritis Advisory Committee (AAC) to evaluate Lilly’s resubmitted NDA for the approval of the JAK inhibitor baricitinib for use in rheumatoid arthritis (RA).
The monoclonal antibody epratuzumab showed promise as a B-cell depleting agent in patients with concomitant systemic lupus erythematosus (SLE) and Sjogren's syndrome, a post-hoc analysis of two phase III trials found.
FDA staff remain worried about the safety of baricitinib, an oral JAK inhibitor intended for treatment of rheumatoid arthritis, according to briefing documents prepared for an advisory committee meeting on Monday.
The PRECISION study took 11 years and 24,081 patients (90% OA; 10% RA).
I suspect that everyone in rheumatology has a special place in their hearts for lupus patients. Their disease is so cruel, and we have so little to offer them, but the young women (and some men) that I treat keep battling on. The longer I have cared for them, the more I wanted to do for them.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
